GSK plc (GSK, GSK.L) has disclosed the primary findings from the FIRST-ENGOT-OV44 phase III trial, which assesses the efficacy of Zejula and Jemperli in treating advanced ovarian cancer in the first line. Remarkably, the trial achieved its primary goal of Progression-Free Survival (PFS), showing a statistically significant improvement with the incorporation of dostarlimab alongside the conventional carboplatin-paclitaxel chemotherapy and niraparib maintenance, with the option of including bevacizumab. However, the company noted that the crucial secondary goal of overall survival did not achieve statistical significance.
Hesham Abdullah, Senior Vice President and Global Head of Oncology Research and Development at GSK, commented, "In line with our commitment to advancing treatments in gynecological cancers, we are rigorously exploring the potential of this therapeutic combination and eagerly anticipate unveiling the comprehensive trial findings."
